ADC Contract Manufacturing Market CAGR To be Around 12.2% by 2035, Due To The Growing Demand For Antibody Drug Conjugates| Roots Analysis

According to our latest market report "ADC Contract Manufacturing Market (6th Edition): Industry Trends and Global Forecasts, till 2035 by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Antibody Isotype, Type of Payload, Type of Linker and Key Geographical Regions", the global ADC contract manufacturing market size is projected to reach USD 6.8 billion by 2035 from USD 1.79 billion in 2024 and USD 2.18 billion in 2025, growing at a CAGR of 12.2% in the forecast period 2025-2035.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/adc-contract-manufacturing-market/request-quote.html

Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered significant attention of pharmaceutical companies, and academic / research institutions across the globe. ADCs are believed to be more efficient and effective in specifically identifying and eliminating cells / pathogens that are associated with disease. However, the manufacturing of ADC therapeutics requires extensive technical capabilities for both biologics, as well as chemical drug substances. The complexity of the manufacturing process is further increased by the need for facilities that strictly follow the cGMP (current good manufacturing practices) criteria and guidelines for standard bio-molecule production, and extensive expertise and technical requirements. Therefore, outsourcing production operations to contract manufacturers has been demonstrated to be an effective approach to mitigate the existing concerns in recent years. In fact, more players are relying on the expertise of such third-party service providers to conduct the manufacturing of their ADC therapeutics in a timely and cost-efficient manner. Therefore, the domain is likely to witness lucrative opportunities in the foreseen future.

ADC Contract Manufacturing Market Segments
Based on stage of development, the market is segmented into Phase I, Phase II, Phase III and Commercial.

1. The commercial segment led the ADC contract manufacturing market, capturing the largest revenue share of over 70.0% in 2023.
2. The commercial segment is anticipated to show the highest annual growth rate of over 16% during the forecast period.

Based on process component, the market is segmented into Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish.

1. The antibody component led the ADC contract manufacturing market, capturing the largest revenue share of 40.0% in 2023.
2. Owing to the intricacies and complexities associated with the manufacturing of antibodies, this trend is expected to remain same during the forecast period.

Based on target indication, the market is segmented into Solid Tumors, Hematological Tumors and other tumors.

1. The solid tumors segment led the ADC contract manufacturing market, capturing the largest revenue share of over 50.0% in 2023.
2. The hematological tumors segment is anticipated to show an annual growth rate of 13% during the forecast period.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/adc-contract-manufacturing-market/request-sample.html

Based on antibody generation, the market is segmented into Second Generation, Third Generation, Fourth Generation and Next Generation.

1. The third generation segment led the ADC contract manufacturing market for antibody component, capturing the largest revenue share of 45.0% in 2023.
2. The fourth generation and next generation segments are anticipated to show an annual growth potential of 17%, each during the forecast period.

Based on antibody origin, the market is segmented into Human, Chimeric, Murine and other origins.

1. The human origin segment led the ADC contract manufacturing market for antibody component, capturing the largest revenue share of 60.0% in 2023.
2. The chimeric origin segment is anticipated to show an annual growth rate of 16% during the forecast period.

Based on antibody isotype, the market is segmented into IgG1, IgG4 and other isotypes.

1. The IgG1 isotype segment led the ADC contract manufacturing market for antibody component, capturing the largest revenue share of nearly 95.0% in 2023.
2. The IgG4 isotype segment is anticipated to show an annual growth rate of 17% during the forecast period.

Based on type of payload, the market is segmented into Auristatin, Camptothecin, DNA Topoisomerase I Inhibitor, Maytansinoid and others.

1. The camptothecin payload segment led the ADC contract manufacturing market for HPAPI / cytotoxic payload component, capturing the largest revenue share of 42.0% in 2023.
2. The maytansinoid payload segment is anticipated to show an annual growth rate of 17% during the forecast period.

Based on type of linker, the market is segmented into Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and other linkers.

1. The maleimide linker segment led the ADC contract manufacturing market for conjugation / linker component, capturing the largest revenue share of 28.0% in 2023.
2. The maleimide linker segment is anticipated to show an annual growth rate of 16% during the forecast period.

Based on key geographical regions, the market is segmented into North America, Europe, Asia Pacific and Rest of the World

1. North America dominated the ADC contract manufacturing market and accounted for the largest revenue share of about 46.0% in 2023.
2. In Europe, the ADC contract manufacturing market is anticipated to demonstrate lucrative growth during the forecast period.

ADC Contract Manufacturing Market Regional Outlook
Based on the key geographical regions, the ADC contract manufacturing market can be segmented into three major regions, including North America, Europe, Asia-Pacific and rest of the world. Led by the US, North America is anticipated to capture the majority share of the ADC contract manufacturing market in 2024 and this trend is likely to remain unchanged during the forecast period. Further, the demand for ADC therapeutics is growing at a faster rate in Europe, acting as an impetus for the growth of the ADC contract manufacturing market in this region.

Key Report Takeaways
1. Currently, 30 manufacturers claim to have the required capabilities to offer contract manufacturing and conjugation services for antibody drug conjugates, worldwide
2. In pursuit of building a competitive edge, industry stakeholders are actively upgrading their existing capabilities and augmenting their service portfolios to become one-stop shops for ADC manufacturing
3. Majority of the trials focused on ADC therapeutics were registered in the last two years; 57% of the total clinical trial studies are being conducted across different sites in the US
4. Industry players are making extensive efforts to expand their existing capacities, capabilities and facilities to augment their ADC related service portfolio
5. ADC therapeutic developers are anticipated to forge strategic alliances with contract manufacturing service providers in order to outsource complex manufacturing operations
6. Over 80% of the current demand for ADC therapeutics is generated by commercialized therapeutics targeted for solid tumors; by 2035, 45% of the demand is likely to be generated in North America
7. The global installed contract ADC manufacturing capacity is spread across various geographies; over 90% of the current installed capacity is available with large contract manufacturers
8. With nearly 70% of the ADC manufacturing operations currently being outsourced, we expect the market to grow at an annualized rate of over 14% over the next decade

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/adc-contract-manufacturing-market/218.html

ADC Contract Manufacturing Market Key Players
Examples of key companies engaged in ADC contract manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include, AbbVie Contract Manufacturing, Abzena, CARBOGEN AMCIS, Catalent Pharma Solutions, Cerbios-Pharma, Formosa Laboratories, GBI, Lonza, MabPlex, Millipore Sigma, Piramal Pharma Solutions, Sterling Pharma Solutions and WuXi Biologics.

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.